CARDIFF, Calif., Jan. 27 Jedi Mind, Inc. (www.jedimindinc.com) (Pink Sheets: JEDM) announced today that Jedi Mind's Head of their Medical Division, Dr. Gordon Chiu commented on his new position with Jedi Mind, Inc. Earlier last year, on December 7th 2009, Jedi Mind, Inc. announced that Dr. Gordon Chiu would also join the company's advisory board.
Advertisement
"Extensive independent tests were conducted to validate the possibility of going beyond video game based software and into medical related software to address areas from learning impairments to severe clinical disorders. The results were very positive," said Dr. Chiu, Head of Jedi Mind's Medical Division. "Over the past decade, hundreds of exploratory devices and discoveries have been accomplished in brain-computer interface (BCI) technology. Breakthrough neural communications allowing electroencephalographic (EEG) activity recorded at the scalp or single-unit activity recorded within the cortex exist. This allows a physically challenged individual to move a virtual computer cursor, select letters to create words or even operate a neural prosthetic device.
Advertisement
"The cornerstone of such success lies in the proper translation algorithm coupled with BCI devices to execute these breakthrough inventions. In fact, each application requires a unique translational algorithm. Unfortunately, development in BCI hardware has significantly outpaced translational algorithms and software. Such applications have a role in neural-medicine, stress, anger, fear etc. Jedi Mind's Medical Division would address this need by allowing every BCI device and manufacturer to work with our company. If humanity is going to make progress in medicine by combining biology and engineering better known as bionics, continued advancements in translational algorithms will be necessary."
"This strategy and achievement would significantly increase our valuation. Unique translational algorithms and source codes opens more opportunities in applications and enhances the business relationships for the company," said Brent Fouch, CEO of Jedi Mind Inc.
"There is a growing demand to develop and to own translational algorithms for unique medical applications. One example involves how music interfaces with translational algorithms into interesting medical applications. Positive results that are described in Dr. Oliver Sacks' book Musicophilia indicate how music can move patients to heights and depths of emotions. In 2009, another breakthrough was published in the Annals of the New York Academy of Sciences (Ref: 2009 July;1169:342-5) mentioning that certain musical patterns could reach Alzheimer's patients even at the end stages of dementia. Powerful applications would be an incredible win-win-win for BCI manufacturers, Jedi Mind and the end user," concluded Dr. Chiu. About Dr. Gordon Chiu:Dr. Chiu has worked as a research scientist for both Pfizer Inc. and Merck?&?Co.?Inc. and has healthcare and marketing experience with strong links to Wall Street and Asia. Dr. Chiu has more than 15 years of combined domestic and international experience in biomedical, chemical, cosmetic, medical and technology industries. He has served on numerous boards and advisory boards of both public and private companies. His solid background and broad experience has allowed him to accomplish and advise in areas of Alzheimer's research, antimicrobial research, breast cancer research, dermatology, drug addictions research, and green technology. He graduated with a B.S. degree from Rensselaer Polytechnic Institute with a summa cum laude. He graduated with an M.S. degree from Seton Hall University with high honors. Additionally, Dr. Chiu was accepted as an MD/PhD candidate under the National Institutes of Health's Medical Scientist Training Program for four years at the Mount Sinai School of Medicine where he also researched, developed, consulted and advised the Department of Dermatology's Dr. Huachen Wei in skin cancer research. Seeing the opportunity to impact foreign policies in healthcare, he transferred his credentials to University of Bridgeport School of Naturopathic Medicine to receive his doctorate in naturopathic medicine. With this unique background, he has investigated the validity of foreign treatments and their success level for public health. He has also been chosen to serve as an advisory role in the identification of low cost solutions (i.e. non-invasive diagnostic equipment) for emerging countries that cannot afford to maintain armies of physicians across numerous sub-specialties. His years of experience and continuous involvement have created deep relationships within the scientific, business, and medical communities. Dr. Chiu developed and owns methodologies called directed combinatorial algorithmic libraries (D.C.A.L.) that are used in various research and commercial applications.
www.JediMindInc.com
[email protected]
Investor Relations (760) 635-2595
From time to time, the Company may issue news releases that contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the safe harbor created by those sections. This material may contain statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. For those statements, the Company claims the protection of the safe harbor for forward-looking statement provisions contained in the Private Securities Litigation Reform Act of 1995 and any amendments thereto. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact and may be "forward-looking statements." "Forward-looking statements" are based upon expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those anticipated.
SOURCE Jedi Mind, Inc.
